impact of glp-1 drugs on industries Drug Adoption Consumer Food Demand GLP-1 Drugs Drop More Than
Description
Even more concerning
Learn what research reveals about GLP-1 effects on energy expenditure.
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.
In these cardiovascular safety trials, in secondary or exploratory analyses, GLP-1 receptor agonists were also shown to reduce macro-albuminuria, an accepted surrogate marker for diabetic kidney disease (DKD), a condition that still represents a major unmet medical need
These drugs effectively lower blood glucose levels and provide cardiovascular and renal benefits, making them a preferred treatment option in diabetes care
The approval pertains to the GLP-1 drug dubbed Xianweiying also known as ecnoglutide which Pfizer has just acquired in a billion-dollar deal.
